Business Wire

MA-IBASIS

21.2.2024 08:01:29 CET | Business Wire | Press release

Share
KPN and iBASIS Renew International Services Outsourcing Deal

iBASIS, the leading provider of communications solutions for operators and digital players worldwide, and KPN, the Netherlands’ leading telecom company, announced today that they have renewed their outsourcing agreement for Voice and Mobile services for three years.

Since its sale by KPN in 2019, iBASIS and its global team have been dedicated to bringing KPN best-in-class services, leveraging the group consolidation and economy of scale strategy of its owner, Tofane Global. Cost stability, capacity planning, and fraud prevention have been instrumental in sustaining the Dutch operator’s traffic growth.

The renewal underscores the success of iBASIS’ model and long-term relationship with managing KPN’s international traffic growth, including IPX cooperation to handle the surge in mobile data traffic. iBASIS reports an 80% year-on-year growth in Diameter traffic, which has enabled KPN to deliver reliable, high-speed data roaming services to its subscribers. The network scalability has been critical in meeting the explosive 4G and 5G mobile data roaming demand, including traffic peaks resulting from the rise of M2M connections.

“iBASIS has been a trusted partner of KPN for the past six years, managing our international voice and mobile services. Leveraging their consolidation model and economies of scale, we outsource nearly 100% of our voice business to iBASIS. Their partner program is focused on delivering quality, transparency, and actionable business insights,” said Michel van Wissen, Executive Vice President, Wholesale, KPN. “We have extended our partnership for another three years. Our excitement is based on proven past successes and on the innovation iBASIS continues to demonstrate in meeting the challenges providers face now and in the future.”

Outsourcing international voice and mobile services also enables KPN to focus on its retail and wholesale business as well as technology initiatives associated with developing these segments.

“We enjoy a strong and mutually beneficial relationship with KPN on voice and mobile services,” added Edwin van Ierland, CEO, iBASIS Voice & Mobile Data. “We are more than a supplier; we are a growth partner. As such, we are very motivated to help KPN leverage our global platform and capabilities to the fullest. The renewal illustrates our excellent relationship, centered on transparency and open communication. It again demonstrates that the outsourcing model chosen by KPN is highly effective.”

“KPN’s three-year renewal is the recognition of iBASIS/Tofane past and future excellence thanks to our unique mix of scale, innovation, and entrepreneurship,” said Alexandre Pébereau, Group CEO and Founder, Tofane Global. “Our performance is recognized again by ROCCO as a top Tier One International Voice Carrier,* Telegeography Fourth Voice Carrier,** and First Independent Carrier.”

In 2023, iBASIS was ranked by 227 MNOs as the top Tier One International Voice Carrier for Performance, Performance+, Leadership, General Rating, and Overall Rating, with the highest results for Global Presence, Local Expertise, R&D Investment, Trusted, Innovative, Dynamic, and Enabler.*

*ROCCO Research: International Voice Carrier Market Impact Report 2023
**Telegeography International Voice Report 2024

About iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist and Tier One IPX vendor with 800+ LTE destinations. iBASIS today serves 1,000+ customers across 28 locations worldwide. iBASIS optimizes global connectivity, quality, and security so customers achieve high return on voice, SMS A2P messaging, mobile data, 5G roaming, and IoT.

About KPN
KPN has been the leading provider of telecommunications and IT services in the Netherlands for almost 140 years. Everyone in the Netherlands uses the KPN network on a daily basis, either directly or indirectly, from the high-speed fibre networks in the ground to payment card machines in shops, or the matrix boards above the motorways. Via the network of the Netherlands, in which KPN continuously invests by rolling out fibre and the introduction of new technologies such as the 5G mobile network, KPN serves consumers and business customers with services for telephony, data, television, internet-of-things, cloud, workplaces and security. KPN has an open network on which other providers also offer services. More information is available at www.kpn.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240220905856/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye